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Peritoneal dialysis (PD) is a successful dialysis modality that enables patients with end-stage kidney disease to have a 
home-based treatment with many advantages for their qual-
ity of life. In general, survival outcomes of PD are equal to 
those of hemodialysis (HD). The reported technique success 
of PD is, however, shorter than that of HD. Whereas there are 
“positive” reasons for stopping PD, such as transplantation 
or recovery of renal function, some patients transfer to HD 
because of peritonitis, inadequate small solute clearance and/
or ultrafiltration (UF), and social factors (1). “Adequacy” and 
“problems with maintaining euvolemia” as reasons for drop-
out increase over time, especially as residual renal function 
declines. Nevertheless, even anuric patients can be maintained 
successfully on PD (2). Many patients are reluctant to transfer 
to HD, even when clinically indicated, because they perceive 
that such a transfer would adversely affect their quality of 
life. A proper presentation of, and possible use of decision 
aids about different renal replacement therapies, including 
home HD and the option of conservative care, from the start 
of treatment onward (integrated care) could potentially reduce 
disappointment when a transfer is needed (3–5).
One of the potential, although extremely rare, complica-
tions of long-term PD is encapsulating peritoneal sclerosis 
(EPS); it is associated with high morbidity related to bowel 
obstruction and malnutrition. The reported mortality of this 
condition is around 50%, usually within 12 months of the diag-
nosis (6,7). Mortality rates, however, depend upon severity of 
the disease, and not all deaths are due directly to EPS alone 
(7). It has been advocated by some that there should be a time 
limit for PD to prevent patients from developing this potentially 
devastating complication. 
The principal aims of this paper are:
1. To review existing information about the epidemiology of 
EPS and its risk factors;
2. To determine whether there are any predictors for the 
development of EPS that would guide the decision to stop 
PD and transfer to HD; and
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3. To reach a consensus that should be given to nephrologists 
and their patients about the length of time that is advisable 
to remain on PD.
GUIDELINES FOR EPS
Guidelines on the topic of EPS have been issued by the 
Japanese Society for Peritoneal Dialysis (8), the UK Renal 
Association (9), and the Dutch EPS Registry (10). When read-
ing the guidelines, it is clear that issuing evidence-based 
guidelines on EPS is being hampered by:
•	 A lack of well-defined diagnostic criteria, especially to 
determine early stages of EPS;
•	 A lack of interventions that consistently improve outcome 
of EPS, even after PD has been stopped;
•	 The fact that EPS may develop or symptomatically progress 
after discontinuation of PD (11) and transfer to HD or 
transplantation, making guidance about when to transfer 
patients electively from PD to HD particularly difficult;
•	 A lack of epidemiological data in different dialysis popula-
tions relating length of time on PD to odds of developing 
EPS (EPS has, however, rarely been reported to occur before 
3 years on PD); and 
•	 Difficulties determining individual risk and impact for 
transfer to HD given their comorbidities, personal situation, 
tolerance of HD, and need for vascular access.
EPIDEMIOLOGY OF EPS
Encapsulating peritoneal sclerosis is a very uncommon com-
plication of PD. Its risk of occurrence has been demonstrated 
to vary markedly among centers, among countries, and over 
time (Table 1). Based on the reports of various single-center, 
multi-center, and national registry observational cohort stud-
ies, the prevalence of EPS has been observed to vary between 
0.4% and 8.9%, its incidence rate between 0.7 and 13.6 per 
1,000 patient-years, and its risk of occurrence after 5 years 
on PD between 0.6% and 6.6% (Table 1). A variable (0 – 71%) 
proportion of EPS cases are not diagnosed until after comple-
tion of PD (12,13), including following kidney transplantation 
(14). The appreciable variability in observed EPS incidence, 
prevalence, and timing of occurrence may be related to 
genetic factors, differences in PD care (e.g. daily prescribed 
PD volumes, dialysate glucose exposure, use of biocompatible 
fluids, peritonitis prevention strategies, time spent on PD, 
etc.), or limitations of the studies published to date, includ-
ing ascertainment bias, detection bias (e.g. under-diagnosing 
mild cases, over-diagnosing simple peritoneal fibrosis, lack 
of a reliable screening test, and failure to monitor patients 
following PD completion), inadequate length of follow-up 
(considering the usually long lag time to development of EPS 
following PD commencement), and inadequate sample size 
(thousands of patients need to be followed for many years 
to provide sufficiently precise statistical estimates of risk for 
informing clinical decision-making) (15). Most studies to date 
have also failed to consider the competing risks of death and 
kidney transplantation (15).
Some studies from Germany (16), Spain (17), Japan (18), 
Australia (13,19), and the Netherlands (20) have further 
suggested that the incidence of EPS may be decreasing over 
time, although the reported incidence/prevalence estimates 
have been too imprecise to be certain of this. If EPS is indeed 
becoming less common, the reasons remain uncertain. 
Most studies have consistently identified increasing PD 
duration as a key risk factor for development of EPS (Table 1) 
(11,12,18,21–27). Other parameters that have been identified 
in at least 1 study to be possible risk factors for EPS include 
higher dialysate glucose exposure, use of conventional PD solu-
tions (as opposed to biocompatible PD solutions), peritonitis 
(frequent, severe, or prolonged), younger age (presumably 
because of lower competing risk of death), abdominal sur-
gery, β-blocker use, icodextrin use, kidney transplantation, 
UF failure, and higher peritoneal solute transport rate (PSTR) 
(13,20–22,25,28–32). However, these data have been too 
imprecise and/or inconsistent to be considered reliable at 
this time.
It should be stressed that all current data indicate that 
the majority of patients receiving PD for a long duration do 
not develop EPS. Clinicians switching patients who have been 
on PD for several years to HD in an attempt to pre-emptively 
circumvent the risk of EPS (0.7 – 9.5 episodes per 1,000 
patient-years) should consider the alternative risks of HD 
complications, including arteriovenous fistula failure (47% 
at 1 year) (42), bacteremia (137 episodes per 1,000 patient-
years) (43), and endocarditis (1.7 – 4.8 episodes per 1,000 
patient-years) (45,46). Other devastating complications of HD 
with consequences as potentially dire as EPS include embolic 
stroke from vegetations caused by endocarditis (47), other 
metastatic complications of bloodstream infections including 
osteomyelitis and spinal epidural abscess (48), and central 
venous stenosis (49). Although these conditions appear to be 
at least as prevalent as EPS in PD patients, the literature on 
these complications is scant.
DIAGNOSIS OF EPS
The diagnosis of EPS is based on a combination of structural 
(e.g. computed tomography [CT] scan appearance) and func-
tional features (intermittent subacute bowel obstruction). It 
is important to be clinically aware of the possibility of EPS for 
many years after stopping PD; failure to listen to the patient 
and his/her symptoms may lead to a delay in diagnosis (50). 
Encapsulating peritoneal sclerosis presents after withdrawal 
from PD in the majority (70 – 90% in some series) of patients 
(11,51) and the time from cessation of PD until the develop-
ment of EPS has been reported as up to 5 years (52). The 
diagnosis is clinical, relies on a constellation of symptoms, 
and can be confirmed radiologically. Changes in the perito-
neum need to be differentiated from those of long-term PD. 
Only a fibrous cocoon wrapped around the bowel is diagnos-
tic; a thickened peritoneal membrane and intra-abdominal 
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TABLE 1 
Studies Examining the Epidemiology of EPS* 
EPS epidemiology
Country
Time
period Study design N Prevalence
Incidence rate
(/1,000 
patient-yrs) Risk with time Reference
Iran 1995–2012 2-center, 
retrospective, 
observational cohort
464 8.9% 7 ≥4	yrs:	8.6%
≥5	yrs:	10.8%
≥6	yrs:	23.3%
≥7	yrs:	25%
Alatab et al. 
2017 (21)
Germany 1997–2015 Single-center, 
retrospective, 
observational cohort
745 
(catheters)
4% (1995–2000)
0% (2001–2003)
5% (2004–2006)
11% (2007–2009)
15% (2010–2012)
5% (2013–2015)
15% (2010–2012)
NA NA Kitterer et al. 
2016 (16)
Scotland 2000–2007 Scottish 
Renal Registry
1,238 2.8% 8.7 (by 2007)
13.6 (by 2014)
1 yr: 1.1%
3 yrs: 3.4%
4 yrs: 8.8%
5 yrs: 9.4%
7 yrs: 22.2%
Petrie et al. 
2016 (24)
Italy 1979–2013 Single-center, 
retrospective, 
observational cohort
920 2.8% 9.5 <2 yrs: 3%
2–4 yrs: 3%
4–6 yrs: 4%
6–8 yrs: 6%
8–10 yrs: 8%
10–12 yrs: 18%
12–14 yrs: 75%
>14 yrs: 67%
Vizzardi et al. 
2016 (27)
Japan 1987–2013 Single-center, 
retrospective, 
observational cohort
270 4.8% NA NA Yamahatsu  
et al. 2015 
(33)
Spain 1980–2012 Single-center, 
retrospective, 
observational cohort
679 2.9% (overall)
5.6% (1980–1990)
3.9% (1991–2000)
0.3% (2000–2012)
NA NA De Sousa-
Amorim et al. 
2014 (17)
Japan 2008–2012 Multicenter, 
prospective 
observational cohort 
(55 centers)
1,338 1.0% 2.3 <3 yrs: 0.3%
5 yrs: 0.6%
8 yrs: 2.3%
>8 yrs: 1.2%
Nakayama  
et al. 2014 
(18)
Korea 2001–2011 Single-center, 
retrospective, 
observational cohort
606 1.3% 1.4 NA Hong et al. 
2013 (34)
Italy 1986–2011 Italian Registry of 
Pediatric Chronic 
Dialysis
712
(children)
1.9% NA <5 yrs: 0.45%
≥5	yrs:	21.1%
Vidal et al. 
2013 (26)
Europe 2001–2010 Multicenter, 
retrospective 
observational cohort 
(European Paediatric 
Dialysis Working  
Group, 14 centers)
1,472
(children)
1.5% 8.7 NA Shroff et al. 
2013 (35)
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TABLE 1 (cont’d)
EPS epidemiology
Country
Time
period Study design N Prevalence
Incidence rate
(/1,000 
patient-yrs) Risk with time Reference
USA 1998–2003 Single-center, 
retrospective, 
observational cohort
76 18.4% (>5 yrs) NA NA Gayomali et al. 
2011 (37)
Netherlands 1 January 
1996 – 1 July 
2007
Multicenter 
case-control study
2,022 2.7% NA NA Korte et al. 
2011 (29)
USA 1979–2009 Single-center, 
retrospective, 
observational cohort
676 1.2% NA ≥6	yrs:	15%
≥9	yrs:	38%
Bansal et al. 
2010 (22)
Canada 1974–2008 Single-center, 
retrospective, 
observational cohort
1,966 1.1% NA NA Trigka et al. 
2011 (38)
Ireland 1989–2008 Single-center, 
retrospective, 
observational cohort
615 1.98% 3.2 ≥6	yrs:	20%
≥8	yrs:	100%
Phelan et al. 
2010 (25)
Australia and 
New Zealand
1995–2007 Binational Registry 
(ANZDATA)
7,618 0.4% 1.8 3 yrs: 0.3%
5 yrs: 0.8%
8 yrs: 3.9%
Johnson et al. 
2010 (13)
Slovenia 1983–2003 Single-center, 
retrospective, 
observational cohort
423 1.2% NA NA Lindic et al. 
2009 (39)
Scotland 2000–2007 Scottish 
Renal Registry
1,238 1.5% 4.9 <1 yr: 0%
1–2 yrs: 0.6%
>2–3 yrs: 2.0%
>3–4 yrs: 3.5%
>4–5 yrs: 8.1%
>5–6 yrs: 8.8%
>6 yrs: 5%
Brown et al. 
2009 (7)
Turkey 1989–2003 Single-center, 
retrospective, 
observational cohort
104
(children)
1.9% NA NA Ekim et al. 
2005 (40)
Korea 1981–2002 Multicenter, 
retrospective 
observational cohort  
(7 centers)
4,290 0.79%
(center variation 
0.28–2.86%)
NA NA Kim et al.  
2005 (28)
Japan April 1999– 
March 2003
Multicenter,  
prospective 
observational cohort  
(57 centers)
1,958 2.5% NA 3 yrs: 0%
5 yrs: 0.7%
8 yrs: 2.1%
10 yrs: 5.9%
15 yrs: 5.8%
>15 yrs: 17.2%
Kawanishi  
et al.  
2004 (11)
Korea 1981–2002 Multicenter, 
retrospective 
observational cohort  
(5 centers)
3,888 0.8% NA NA Lee et al.  
2003 (30)
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adhesions are common in long-term PD and after peritonitis, 
particularly tuberculous peritonitis, and are therefore not 
diagnostic (52).
Clinical Features of EPS: The diagnosis of EPS is based on a 
combination of bowel obstruction and features of encapsula-
tion due to peritoneal fibrosis. Symptoms such as anorexia, 
nausea, vomiting, and weight loss are common. In addition, the 
step-wise process of symptom progression is important. If the 
capsule formed is too thin to impair intestinal peristalsis, EPS 
does not develop (encapsulating stage). However, if the cap-
sule thickens with time, bowel obstruction symptoms appear 
(ileus stage). These symptoms improve by temporary fasting, 
but recur several months later. If the time to recurrence gradu-
ally shortens, EPS is diagnosed. Clinically, this progression 
manifests itself with early symptoms (bloody ascites, appetite 
loss, nausea, diarrhea, and abdominal pain), progressing to 
more severe symptoms, including constipation and abdominal 
mass accompanied by severe malnutrition and weight loss. 
Sometimes, early EPS presents with an inflammatory state 
including fever, general fatigue, and slight weight loss, with 
an elevated C-reactive protein, anemia, and hypoalbuminemia. 
The intermittent progression, and therefore symptoms, of EPS 
is a useful distinguishing feature from other gastrointestinal 
disorders (53). 
Radiological Diagnosis of EPS: Of the techniques available, 
computed tomographic (CT) scanning has been reported as 
having the most discriminant value (52). It is also widely 
available and has the greatest reproducibility. Computed 
tomographic scanning is therefore recommended as the 
first investigation. The features that have been shown to 
have a high degree of agreement among radiologists are 
peritoneal calcification, bowel thickening, bowel tether-
ing, and bowel dilatation (54,55). It should be stressed that 
finding these changes on CT scan does not suffice to make 
the diagnosis of EPS, especially not in the absence of the 
symptoms described above. Many long-term PD patients will 
have thickening of the peritoneal membrane without any 
features of EPS.
Pathological Features of EPS: A characteristic macro-
scopic appearance is observed at laparotomy or laparoscopy. 
Histological changes that are characteristic of EPS have been 
described but are not specific and overlap with membrane 
changes that occur with UF failure and infectious peritonitis in 
long-term PD (56). Thus, an “opportunistic” peritoneal biopsy 
at the time of incidental abdominal surgery in the absence of 
other features of EPS may be misleading and should not be 
used to make a diagnosis of EPS.
Membrane Transport Characteristics: Changes in PSTR are 
frequent in PD. It has been recognized for many years that UF 
capacity falls and there is an increase in PSTR prior to develop-
ment of EPS (57). These membrane changes are, however, also 
commonly observed in patients on long-term PD who do not 
TABLE 1 (cont’d)
EPS epidemiology
Country
Time
period Study design N Prevalence
Incidence rate
(/1,000 
patient-yrs) Risk with time Reference
Japan April 1999–
March 2001
Multicenter, 
retrospective 
observational cohort 
(64 centers)
2,216 0.77% NA <5 yrs: 0.3% 
≥5	to	<10	yrs:	0.5%
≥10	yrs:	3.3%
Kawanishi  
et al.  
2001 (12)
Japan 1981–1995 Multicenter, 
retrospective 
observational cohort 
(60 centers)
687
(children)
1.6% NA ≥5	yrs:	6.6%
≥8	yrs:	12%
Hoshii et al. 
2000 (41)
Australia 1980–1994 Multicenter, 
retrospective 
observational cohort
7,374 0.7% 1.9 (1980–1989)
4.2 (1990–1994)
>2 yrs: 1.9%
>5 yrs: 5%
>6 yrs: 10.8%
>8 yrs: 19.4%
Rigby and 
Hawley  
1998 (19)
Japan 1982–1996 Single-center, 
retrospective, 
observational cohort
197 3.7% 2.6 NA Yokota et al. 
1997 (42)
Netherlands 1979–1995 Single-center,  
case-control
407 3.9% 3.5 NA Hendriks et al. 
1997 (32)
EPS = encapsulating peritoneal sclerosis; NA = not applicable.
*Presented in order of publication from most recent to oldest.
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develop EPS. The Pan-Thames EPS study showed that, while 
the majority of patients had high PSTR, some developed EPS 
in the absence of these membrane changes and had good UF 
(6). These changes are discussed in more detail in the section 
on predicting EPS. 
MANAGEMENT OF EPS
It is generally accepted that, after a diagnosis of EPS, PD 
should be discontinued and the patient transferred to HD. 
However, it should be considered that some cases of EPS 
are clinically less severe and potentially could worsen upon 
stopping PD. The eventual risks of HD (access, access-related 
infection, hemodynamic intolerance, lifestyle issues, and 
patient preference) should also be considered carefully in 
a discussion with the patient about the best future renal 
replacement therapy option. Generally, the PD catheter 
is removed on discontinuing PD. Some patients in Japan 
have been managed by leaving the catheter in situ to apply 
regular peritoneal lavage (58,59). It is unclear whether this 
process has any beneficial effects by removing mediators 
of the peritoneal fibrotic process, or whether the catheter 
and irrigation fluid could act as a further stimulus to the 
EPS process.
Nutritional support (often by parenteral nutrition) is 
crucial in patients with EPS, many of whom will recover with 
conservative treatment (60). In addition, drug therapies that 
have been reported to have beneficial effects in EPS include 
corticosteroids (11,61), tamoxifen (62–64), and immuno-
suppression (65–67). The fact that EPS can actually develop 
following renal transplantation in patients already receiving 
corticosteroids and/or other immunosuppressive agents may, 
at least theoretically, argue against any therapeutic benefit 
of these drugs. Most of these reports are limited to isolated 
cases or relatively small series, have not been uniformly suc-
cessful, and are potentially limited by other interventions, 
selection, and positive publication biases. The 2 larger studies 
gave conflicting results. The study from the Netherlands (63 
patients) found that the mortality of the tamoxifen group 
was lower than those not given the drug (64). In contrast, 
in a large UK series (111 patients), there was no difference 
in outcomes for patients treated with steroids, immunosup-
pression, tamoxifen, or combinations of these compared 
with patients that were not (6). No definitive conclusions 
can therefore be drawn at this time about their value in the 
management of EPS. 
On the basis of successful surgical results from Japan 
(51,68,69), aggressive surgical treatment for when there was 
no improvement of bowel obstruction was started in the UK 
(70) and Germany (71,72). From these reports, it appears that 
with surgery, EPS mortality rate declines to 32 – 35%. It must 
be stated, though, that for surgical results to be successful, 
the surgical team must have a thorough understanding of the 
pathology of EPS. Such surgery should therefore only be done 
in specialist regional centers that can provide appropriate 
surgical training and patient support.
RENAL TRANSPLANTATION AND EPS
Although there were reports from the UK and the 
Netherlands (73–75), the numbers from these reports are 
small and there is still no evidence of a genuine sustained 
increase in the occurrence of post-transplant EPS. Balanced 
against this, there have been isolated reports of dramatic 
resolution of established EPS following renal transplantation, 
possibly as a result of immunosuppression (76). Indeed, a 
prior diagnosis and treatment of EPS is not a contraindica-
tion to transplantation. Encapsulating peritoneal sclerosis 
occurs after transplantation only in patients who have been 
exposed to PD for several years; there appears to be no risk 
if patients have been on PD for a short time. Ideally, there-
fore, patients should be transplanted within 3 – 4 years of 
starting PD. This requires appropriate patient education, 
efficient workup, access to the national deceased organ 
waiting list, and encouragement of living donation. The 
same is true for patients on HD so that patients can benefit 
from the improved survival and quality of life associated with 
successful transplantation. 
SCREENING FOR EPS
There is no reliable screening tool established for EPS. 
Change in PSTR across the peritoneal membrane is not particu-
larly helpful. A rise in PSTR is common in patients on long-term 
PD and therefore is commonly found in patients subsequently 
developing EPS. As discussed, though, EPS can also occur in 
patients with slow PSTR. Similar observations and conclusions 
apply to loss of UF.
Computed tomographic scanning has been proposed as 
a screening tool, but EPS can occur within a year or less of a 
normal CT scan in asymptomatic patients (77). In contrast, 
long-term patients on PD with minor abdominal symptoms 
in this study were sometimes found to have minor CT scan 
abnormalities; all such patients then progressed to the full 
EPS clinical syndrome on stopping PD. 
PREDICTING EPS
Epidemiology: When predicting the absolute risk of EPS, for 
both clinical and statistical reasons, it is not possible to ignore 
the competing risk of death. Methods such as the Kaplan-Meier 
estimator will not account for competing risks and therefore 
will overestimate the level of risk (78). Work for the Peritoneal 
Dialysis Competitive Risk Analysis for Long-Term Outcomes 
(PD-CRAFT) study using data from the ANZDATA registry and the 
Scottish Renal Registry has verified this phenomenon, showing 
increasing disparity with longer follow-up. As is clearly shown 
in the studies of the epidemiology of EPS, duration of PD is 
strongly associated with EPS risk. In competing risks predic-
tion models for patients in ANZDATA 3 and 5 years after the 
start of PD using age and primary renal disease as predictors 
of mortality and duration of PD as a predictor of EPS, most of 
the variability in EPS incidence was explained (unpublished 
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conductance and abolition of sodium sieving are not associ-
ated with any change in the expression of aquaporin-1 (AQP1) 
water channels in the peritoneal capillaries of patients with 
EPS (97,98). 
Biomarkers: As the current pathophysiological model for 
EPS risk is based on chronic inflammation and fibrosis within 
the peritoneum, the use of biomarkers from the peritoneal 
effluent has been suggested to improve the prediction of 
EPS. They have therefore been tested to assess the risk of 
EPS in 4 different case control studies either fully or par-
tially matched for duration of PD using prospectively collected 
dialysate samples (99–102). The consistent finding is that 
several inflammatory cytokines (interleukin-6, tumor necrosis 
factor-α, monocyte chemoattractant protein-1, chemokine 
ligand 15, and plasminogen activator inhibitor-1) are slightly 
elevated up to several years before EPS, supporting a role 
for chronic peritoneal inflammation in the physiopathol-
ogy of EPS. However, the levels of biomarkers in the effluent 
show significant variability (a lognormal distribution) and 
the differences between cases and controls, whilst statisti-
cally significant, have been small and therefore of debatable 
clinical significance. Whether functional measurements or 
biomarkers, when combined with PD duration and risk fac-
tors for mortality, improve the prediction of EPS has not 
been tested prospectively.
PREVENTION OF EPS
As discussed, the incidence of EPS increases significantly 
with time on PD, particularly after 5 or more years of treatment, 
but the majority of long-term PD patients will not develop EPS. 
Importantly, EPS may develop or worsen after stopping PD. 
There are no prospective data demonstrating any benefit of 
pre-emptively switching long-term PD patients to HD. A modal-
ity switch could also have significant adverse psychosocial and 
medical implications for patients, which need to be considered 
on an individual basis. Long-term access for HD also needs to 
be discussed and planned with the patient; the risk of infection 
from temporary HD access is considerably higher than the low 
risk of EPS at some point in the future.
If considering switching patients from long-term PD to 
HD pre-emptively because of concern about risk of EPS, it 
may be appropriate to select those patients with potentially 
adverse features for a high risk of PD technique failure such 
as high and rising peritoneal permeability, low UF capacity, 
difficulty in fluid balance control, and requirement for high 
glucose concentration dialysate, as well as those with frequent 
episodes of peritonitis. These features would then possibly 
select those at greater risk of PD technique failure. The effect 
of this management on EPS risk is, however, unknown. It would 
be important to ensure that these patients are monitored 
specifically for clinical features of EPS, which can develop 
some time after switching to HD. Informing patients of the 
early signs of EPS was recommended in a study of patient 
experiences in particular at the time of transition to HD as 
data from PD-CRAFT), i.e. the ‘real-world’ risk of EPS is almost 
entirely due to the risk of death and the duration of PD. No 
prediction models are available for clinical usage currently as 
the baseline risk is not yet clear due to the variability in EPS 
incidence described previously.
Despite the very strong effect of the duration of PD and risk 
of mortality, clinicians may wish to further stratify patients 
at risk of EPS. Data on this are not robust enough for strong 
guidance as there are no datasets with sufficiently detailed 
information on the very large populations required to study 
EPS. There are several small, mostly single-center, studies 
that have examined membrane function testing and dialysate 
biomarkers for this purpose, and they have all been predicated 
on the same pathophysiological model for membrane damage.
Membrane Function: As already discussed, longitudinal 
follow-up of peritoneal membrane function has shown that 
EPS is associated with progressive transport defects, including 
excessive increase in PSTR and loss of UF capacity as compared 
with control long-term PD patients (6,29,32,79–88) (summa-
rized in Table 2). As PSTR predominantly reflects peritoneal 
inflammation (89,90) and EPS is an inflammatory condition, 
changes in PSTR appeared a promising risk marker for epi-
demiological and pathophysiological reasons. More recent 
longitudinal studies carefully matched for duration of PD to 
account for the association between PSTR and duration of PD 
(91) suggest that differences in PSTR are apparent only in the 
later stages prior to EPS, therefore limiting its application as 
a potential risk indicator (83,88). 
Progressive uncoupling between solute and water transport 
across the EPS peritoneal membrane (a loss of UF capacity 
disproportionate to the rise in PSTR) (92), thought to be due 
to fibrosis, led to the hypothesis that functional measures of 
this fibrosis may be a more reliable and earlier indicator of the 
risk of EPS (83). This hypothesis was verified in case-control 
series demonstrating a reduction in osmotically-driven water 
flow across the peritoneal membrane (estimated by either 
sodium sieving, free-water transport, or direct assessment of 
osmotic conductance) in EPS patients (89,90). In daily clinical 
practice, the modified 3.86% glucose-based peritoneal equili-
bration test (PET) accurately evaluates UF capacity, allows the 
diagnosis of UF failure (defined as a net UF < 400 mL after 4 h), 
and provides the opportunity to determine sodium sieving, 
estimated either by the change in dialysate-over-plasma ratio 
of sodium or by the dip in dialysate sodium concentration dur-
ing the first hour of the dwell (93). As a biochemical measure, 
it is theoretically more reliable than volumetric assessment 
of UF, which may be highly variable and influenced by other 
factors such as catheter patency.
The combination of functional and structural analysis 
of the membrane of patients with EPS demonstrated that 
reduced osmotic water transport is directly related to the 
degree of fibrosis and to changes in collagen density and 
structure in the peritoneal interstitium (88), in line with 
predictions based on the serial pore-membrane/fiber matrix 
and distributed models (94–96). Of note, the low osmotic 
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TABLE 2 
Case Series and Registry Studies Reporting Data on Membrane Function in Patients with EPS* 
Country
Time 
period Study design
Number 
of EPS 
patients
Number 
of control 
patients
Type of 
 PET
Changes in 
peritoneal 
transport in 
EPS
Predictive  
value of 
peritoneal 
transport 
defects
Mechanistic 
insights Reference
Belgium 1994–
2014
Single-center, 
retrospective, 
observational
7 28, PD 
duration  
and  
gender-
matched
3.86%  
PET
Loss of UF 
capacity, 
fast solute 
transport, 
uncoupling 
between  
water and 
solute 
transport, 
loss of  
sodium  
sieving
Loss of  
sodium sieving 
independently 
associated  
with EPS
Transport 
defects 
linked to 
changes in 
the collagen 
matrix 
of the 
peritoneal 
interstitium. 
Preserved 
expression 
of AQP1 
water 
channels
Morelle et al. 
2015 (88)
Netherlands 1995–
2008
Single-center, 
retrospective, 
observational
12 21 patients 
with UFF  
and 26 
patients 
without  
UFF
SPA, incl. 
3.86%  
PET
Loss of OCG 
and FWT
Loss of FWT 
independently 
associated  
with EPS
— Sampimon et al. 
2014 (87)
Europe 2001–
2010
Multicenter, 
retrospective, 
observational, 
pediatric 
patients
22 1,450 NA UFF in 15/17 
(88%) of 
patients  
on PD
— — Shroff et al. 
2013 (35)
Netherlands 1995–
2008
Single–center, 
retrospective, 
observational
12 21 patients 
with UFF  
and 26 
patients 
without  
UFF
SPA, incl. 
3.86% 4-h 
PET
Loss of UF 
capacity, 
fast solute 
transport, 
loss of FWT 
both in EPS 
and patients 
with UFF 
without EPS.
Lower ELAR in 
EPS than UFF 
patients
21% of patients 
who presented 
UFF eventually 
developed EPS. 
50% of patients 
with UFF who 
continued PD  
for more than  
3 years 
developed  
EPS
— Sampimon et al. 
2011 (85)
Netherlands 1996–
2007
Multicenter, 
retrospective, 
observational
63 126,  
matched  
for date of  
PD start
2.27%  
and  
3.86%  
PET
UFF more 
prevalent 
(60%) in 
EPS than in 
controls  
(15%)
UFF 
independently 
associated  
with EPS
— Korte et al.  
2011 (29)
United Kingdom 2000–
2009
Single-center, 
retrospective, 
observational
39 71, on PD  
for  
>4 years
2.27%  
PET
Fast solute 
transport,  
and loss of  
UF capacity
— — Habib et al. 
2010 (84)
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TABLE 2 (cont’d)
Country
Time 
period Study design
Number 
of EPS 
patients
Number 
of control 
patients
Type of 
 PET
Changes in 
peritoneal 
transport in 
EPS
Predictive  
value of 
peritoneal 
transport 
defects
Mechanistic 
insights Reference
United Kingdom 1990–
2010
Single-center, 
retrospective, 
observational
9 36, PD 
duration  
and age-
matched
2.27%  
PET
Loss of UF 
capacity, 
fast solute 
transport, 
uncoupling 
between  
water and 
solute 
transport
— — Lambie et al. 
2010 (83)
United Kingdom 1997–
2007
Multicenter, 
retrospective, 
observational
111 (63 
with 
peritoneal 
transport 
testing)
— 2.27%  
PET
41/63 (65%) 
with fast  
solute 
transport 
status, 
and 7/63 
(11%) with 
slow solute 
transport 
status at last 
PET
— — Balasubramaniam 
et al.  
2009 (6)
Netherlands 1995–
2006
Single-center, 
retrospective, 
observational
11 — SPA, incl. 
3.86%  
4-h PET
Inverse 
U-shaped 
trend in solute 
transport and 
progressive 
decrease in 
both UF  
and FWT
— — Sampimon et al. 
2007 (82)
Japan — Single-center, 
retrospective, 
observational
18 60, on  
PD for  
>2 years
‘Fast’  
PET
Fast transport 
status
Fast solute 
transport status 
independently 
associated with 
EPS
— Yamamoto et al. 
2005 (81)
Japan <1998 Single-center, 
retrospective, 
observational
12 128 2.27%  
PET
Early onset 
fast solute 
transport 
status and 
UFF in 12/12 
(100%) of EPS 
patients 
— Yamamoto et al. 
2002 (80)
Netherlands 1984–
1997
Single-center, 
retrospective, 
observational
10 30, PD 
duration-
matched
1.36%  
PET
Fast solute 
transport  
and loss  
of UF  
capacity
— — Hendriks et al. 
1997 (32)
EPS = encapsulating peritoneal sclerosis; PET = peritoneal equilibration test; PD = peritoneal dialysis; UF = ultrafiltration; UFF = UF failure; 
AQP1 = aquaporin-1; SPA = standard peritoneal analysis; OCG = osmotic conductance to glucose; FWT = free-water transport; NA = not applicable; 
ELAR = effective lymphatic absorption rate.
* Presented in order of publication from most recent to oldest.
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symptoms were often subtle but not understood. Providing 
written information is recommended to give the patients 
control and enable them to discuss their concerns with the 
healthcare team (50).
Other strategies that have been suggested for EPS preven-
tion include minimization of dialysate glucose administration 
and prescription of “biocompatible” PD fluids. In comparison 
studies of peritoneal biopsy specimens of low GDP and con-
ventional acidic solutions, the neutral solutions with low GDP 
were associated with less peritoneal membrane fibrosis and 
vascular sclerosis through suppression of advanced glycation 
end-product accumulation (103). Moreover, the multicenter 
prospective observation study (the NEXT-PD study) confirmed 
fewer cases of EPS (18). The authors postulated that the use of 
neutral solutions with low GDP may have contributed to this 
observation along with other factors such as discontinuing PD 
in high-risk patients and minimizing use of high-glucose fluids 
with use of icodextrin.
SUMMARY STATEMENTS
1. Encapsulating peritoneal sclerosis is recognized as a 
potential and rare complication of long-term PD, occur-
ring in patients on PD for more than 5 years. Although the 
incidence of EPS then increases with further time on PD, the 
condition remains infrequent and the majority of long-term 
PD patients are not affected. 
2.  The decision about when to discuss EPS as a potential com-
plication of long-term PD therapy should be undertaken at 
some point with the patient—not necessarily at the start of 
PD but more reasonably at the 3 – 4 year point of therapy.
3. Encapsulating peritoneal sclerosis is associated with con-
siderable morbidity and mortality. It is therefore important 
to develop strategies to reduce the risk to an individual 
patient. 
4. No single strategy to reduce the risk of EPS has been proven 
in clinical trials, but there is some evidence to support the 
following:
a. Minimizing dialysate glucose exposure, although it 
is important to ensure that fluid volume status is not 
compromised as a result 
b. Preventing acute PD-related peritonitis using interven-
tions recommended by the ISPD peritonitis guidelines 
(104)
c. Use of neutral-pH, low-glucose degradation product 
dialysis solutions (low-grade evidence only)
5. The more severe clinical features of EPS with bowel obstruc-
tion, poor nutrition, and ascites may develop even if PD is 
discontinued (patient transferred to HD or transplanted).
6. There are no specific predictors for the development of EPS:
a. Although many patients with EPS have high PSTR, this 
is not true for all patients and this is a common finding 
in patients on long-term PD.
b. There is no evidence that CT scanning has any value in 
predicting EPS.
c. Progressive loss of osmotic conductance to glucose 
(uncoupling between water and solute transport, altered 
sodium sieving, decreased free-water transport) may 
reflect the development of peritoneal interstitial fibrosis 
and may help identifying patients at risk of EPS. However, 
this needs to be confirmed in prospective studies.
7. Although changes in peritoneal membrane function, loss 
of UF and frequent peritonitis are poor predictors of EPS, 
they are factors suggesting that transfer to HD should be 
considered and discussed with the patient, if appropriate, 
to optimize dialysis delivery. Such patients should be moni-
tored closely for possible development of EPS if changing 
dialysis modality to HD.
8. Older patients and those with comorbidities have a limited 
life expectancy when starting dialysis. Few will therefore 
survive long enough on PD to be at risk of developing EPS. 
Such patients are unlikely to be candidates for transplanta-
tion so their quality of life on dialysis is very important. In 
considering discussing the risk of EPS with such a patient, 
it is therefore important to consider realistically their life 
expectancy, the feasibility of HD for that patient, and how 
this would affect their quality of life. Discussions with the 
patient should be part of a shared decision-making process 
about overall prognosis and goals of care.
CONCLUSION 
Encapsulating peritoneal sclerosis is a rare condition. There 
is no evidence to withhold PD as a treatment option because 
of fear of development of EPS. There is insufficient evidence 
to support a single rule about optimal length of time on PD to 
avoid the risk of EPS 
Each long-term patient needs to be considered individually, 
taking into account the following factors:
1. Age and prognosis of patient;
2. Length of time on PD; 
3.  Quality of PD (dialysis adequacy, ultrafiltration, peritonitis 
frequency);
4. Access to and suitability for transplantation;
5. Potential risk of HD in the particular patient (hemodynamic 
stability, vascular access); and
6. Quality of life of the patient.
All these items should be discussed and any decision arrived 
at by shared decision-making.
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